首页> 外文期刊>国际肝胆胰疾病杂志(英文版) >Liver transplantation versus liver resection for hepatocellular carcinoma:a meta-analysis
【24h】

Liver transplantation versus liver resection for hepatocellular carcinoma:a meta-analysis

机译:肝移植与肝切除术在肝细胞癌中的荟萃分析

获取原文
获取原文并翻译 | 示例
       

摘要

BACKGROUND: Liver transplantation (LT) and liver resection (LR) are currently considered the standard treatment of patients with hepatocellular carcinoma (HCC). However, the outcomes of LT and LR are still inconclusive. DATA SOURCES: MEDLINE, EMBASE, and Cochrane Library were searched for relevant studies. Surgical safety indices such as  treatment-related  morbidity  and  mortality,  and  efifcacy indices such as overall and tumor-free survival outcomes were evaluated. Weighted mean differences and odds ratios (ORs) were calculated using a random-effects model. RESULTS: Seventeen  studies  were  included  in  this  meta-analysis.  LT  achieved  signiifcantly  higher  rates  of  surgery-related morbidity (OR=1.47; 95% CI: 1.02-2.13) and mortality (OR=2.12; 95% CI: 1.11-4.05). Likewise, the 1-year survival rate was lower in LT (OR=0.86; 95% CI: 0.61-1.20). However, the 3- and 5-year survival rates were signiifcantly higher in LT than in LR and the ORs were 1.12 (95% CI: 0.96-1.30) in 3 years and 1.84 (95% CI: 1.49-2.28) in 5 years. Furthermore, the tumor-free survival rate in LT was signiifcantly higher than that in LR in 1, 3, 5 years after surgery, with the ORs of 1.72 (95% CI: 1.24-2.41), 3.75 (95% CI: 2.94-4.78) and 5.64 (95% CI: 4.35-7.31), respectively. CONCLUSIONS: One-year morbidity and mortality are higher in LT than in LR for patients with HCC. However, long-term survival and tumor-free survival rates are higher in patients treated with LT than those treated with LR.
机译:背景:目前,肝移植(LT)和肝切除(LR)被认为是对肝细胞癌(HCC)患者的标准治疗。但是,LT和LR的结果仍然不确定。 数据来源:检索了MEDLINE,EMBASE和Cochrane图书馆以进行相关研究。评估了与治疗相关的发病率和死亡率等手术安全性指标,以及总体和无肿瘤生存期的疗效和有效性指标。使用随机效应模型计算加权平均差和奇数比(OR)。 结果:该荟萃分析包括“十七项研究”。 LT显着提高了与手术相关的发病率(OR = 1.47; 95%CI:1.02-2.13)和死亡率(OR = 2.12; 95%CI:1.11-4.05)。同样,LTLT中的“ 1年生存率”较低(OR = 0.86; CI的95%CI:0.61-1.20)。但是,LT中的3年和5年生存率显着高于LR中的LLT和OR的生存期,在3年中分别为1.12(95%CI:0.96-1.30)和1.84年中(1.84%(95%CI:1.49-2.28)。 。此外,LT术后1,3,5年的无肿瘤生存率明显高于LR1、3、5年,而OR为1.72(95%CI:1.24-2.41),3.75(95%CI :)。分别为4.78)和5.64(95%CI:4.35-7.31)。 结论:对于肝癌患者,LT的一年发病率和死亡率比LR更高。然而,长期接受生存率和无肿瘤生存率要比接受LR治疗的患者更高。

著录项

  • 来源
    《国际肝胆胰疾病杂志(英文版)》 |2014年第003期|234-241|共8页
  • 作者单位

    Department of Hepatobiliary Surgery Xu XS, Liu C, Qu K, Song YZ and Zhang P and Department of Radiology Zhang YL, First Afifliated Hospital, School of Medicine, Xi'an Jiaotong University, Xi'an 710061, China;

    Department of Hepatobiliary Surgery Xu XS, Liu C, Qu K, Song YZ and Zhang P and Department of Radiology Zhang YL, First Afifliated Hospital, School of Medicine, Xi'an Jiaotong University, Xi'an 710061, China;

    Department of Hepatobiliary Surgery Xu XS, Liu C, Qu K, Song YZ and Zhang P and Department of Radiology Zhang YL, First Afifliated Hospital, School of Medicine, Xi'an Jiaotong University, Xi'an 710061, China;

    Department of Hepatobiliary Surgery Xu XS, Liu C, Qu K, Song YZ and Zhang P and Department of Radiology Zhang YL, First Afifliated Hospital, School of Medicine, Xi'an Jiaotong University, Xi'an 710061, China;

    Department of Hepatobiliary Surgery Xu XS, Liu C, Qu K, Song YZ and Zhang P and Department of Radiology Zhang YL, First Afifliated Hospital, School of Medicine, Xi'an Jiaotong University, Xi'an 710061, China;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

  • 入库时间 2022-08-19 03:39:16
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号